Entrectinib by F. Hoffmann-La Roche for Metastatic Uveal Mel

Entrectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Metastatic Uveal Melanoma.

Related Keywords

Switzerland , Entrectinib Rozlytrek , Roche , Globaldata Pharmaceutical Intelligence Center , Metastatic Uveal , Metastatic Uveal Melanoma , Entrectinib Loa , Phase Transition Success Rate Model , Hoffmann La Roche , Pharmaceutical Intelligence ,